查詢結果分析
相關文獻
- Successful Treatment of a Bulky Seminoma in an Abdominal Undescended Testis: A Case Report
- Ifosfamide-Based Chemotherapy for Previously Treated Lung Cancer Patients
- Treatment of Ultra-High Risk Gestational Trophoblastic Disease by an EMA/CE Regimen
- The Experience of Combination of Chemotherapy and Surgery in Treatment of Advanced Nonseminomatous Germ Cell Tumor of the Testis
- Malignant Primary Extragonadal Germ Cell Tumors of Mediastinum--An Analysis of Clinical and Radiological Features in 15 Cases
- 非小細胞肺癌術前輔助性化學治療的經驗
- Radiation Therapy in Primary Central Nervous System Lymphoma
- Nausea and Vomiting of Cancer Chemotherapy
- 胃癌化學治療之進展
- 5-Fluorouracil的代謝及其高劑量化學治療的神經毒性
頁籤選單縮合
題名 | The Effectiveness of Alizapride as an Antiemetic for Cisplatin-Based Chemotherapy=Alizapride在以Cisplatin為主的抗癌化學療法時的止吐效果 |
---|---|
作者 | 陳瑞堅; 林育弘; 陳祈安; 嚴孟祿; 黃思誠; 周松男; 謝長堯; | 書刊名 | 中華民國婦產科醫學會會刊雜誌 |
卷期 | 36:3 1997.09[民86.09] |
頁次 | 頁101-106 |
分類號 | 418.98 |
關鍵詞 | 化學治療; Alizapride; Antiemetics; Cisplatin; |
語文 | 英文(English) |
中文摘要 | 目的:Alizapride是Benzamide類化合物族類之一種,能抑制大腦嘔吐中樞之 Dopamine接受器。本研究就是要來評估Alizapride作為以Cis- diamminedichloroplatinum(Cisplatin)為主的抗癌化學療法時的止吐效果,以及病人對此藥 的耐受度。 方法:研究對象為30名以含Cisplatin的藥物作化學治療的婦癌病人。每一例病患在給 予Cisplatin之前30分鐘開始給藥,每4小時一次共四次。Metoclopramide劑量則為1.5 mg/kg。兩者的止吐效果、副作用及安全性加以紀錄,並以generalizd Mantel-Haenszel法 加以分析。 結果:在預防內含中劑量Cisplatin之化療所導致之急性及遲發性嘔吐方面,本劑的作 用比metoclopramide為佳(p<0.001)。Alizapride可以減少70%化療後24小時內之嘔吐, 16.7%可以因之完全消除。病人對Alizapride的耐受性很好,使用後僅偶有腹瀉之併發症, 不會有錐體外路症候。 結論:我們認為Alizapride在預防含Cisplatin之化療所引起之嘔吐方面比其他常甲之 metoclopramide為佳。其抗嘔吐效果優良、副作用少、在作此類化學治療時應予採用。 |
英文摘要 | Objective: Alizapride is a member of the family of benzamide compounds. Its potent antiemetic properties come from its inhibition of dopamine receptors in the vomiting center of the central nervous system. The purpose of this study was to assess its antiemetic effects and its tolerability in patients undergoing cis- diamminedichloroplatinum (cisplatin) chemotherapy. Methods: A randomized crossover clinical trial which compared the antiemetic properties of alizapride with those of metoclopramide was undertaken. Thirty patients with gynecological cancer who had just begun a regimen of cisplatin-based chemotherapy were included. The efficacy, side effects, and tolerability of these two agents were recorded and evaluated. Results: When compared with antiemetic regimens which used metoclopramide, alizapride was found to be more effective at preventing chemotherapy-induced vomiting from moderate doses of cisplatin (p <0.001). Alizapride diminished vomiting in the first 24 hours after chemotherapy in 70% of patients, and completely prevented it from occurring in 17% of them. Alizapride appeared to be well tolerated, with diarrhea appearing only rarely as a side effect. It did not produce extrapyramidal effects. Conclusions: Alizapride was superior to metoclopramide in preventing the emesis induced by cisplatin. Our study indicates that alizapride is an effective, apparently well-tolerated agent which can be administered for the prevention of cisplatin- induced nausea and vomiting. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。